Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Financing Activities: 2011-2024

Historic Cash from Financing Activities for Abeona Therapeutics (ABEO) over the last 14 years, with Dec 2024 value amounting to $104.1 million.

  • Abeona Therapeutics' Cash from Financing Activities rose 1826.76% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year decrease of 73.90%. This contributed to the annual value of $104.1 million for FY2024, which is 181.02% up from last year.
  • Per Abeona Therapeutics' latest filing, its Cash from Financing Activities stood at $104.1 million for FY2024, which was up 181.02% from $37.1 million recorded in FY2023.
  • Over the past 5 years, Abeona Therapeutics' Cash from Financing Activities peaked at $104.1 million during FY2024, and registered a low of $1.9 million during FY2020.
  • Its 3-year average for Cash from Financing Activities is $61.5 million, with a median of $43.2 million in 2022.
  • As far as peak fluctuations go, Abeona Therapeutics' Cash from Financing Activities slumped by 98.30% in 2020, and later spiked by 1,184.14% in 2021.
  • Yearly analysis of 5 years shows Abeona Therapeutics' Cash from Financing Activities stood at $1.9 million in 2020, then skyrocketed by 1,184.14% to $24.9 million in 2021, then skyrocketed by 73.66% to $43.2 million in 2022, then declined by 14.17% to $37.1 million in 2023, then surged by 181.02% to $104.1 million in 2024.